Home | Site Map | About | Contact 
  The scientific approach to weight loss and maintenance. Indepenent, hype-free research.
 
Weight Loss Guide
 Weight Loss Basics
 Diets & Dieting
 Drug Therapy
 Supplements
 Weight Loss Surgery
 Tools & Calculators
 Food Analysis
 
News & Research
 Weight Loss News
 Published Studies
   > Drugs
   > Diets
   > Supplements
   > Surgery
   > Lifestyle
 
 
 
 
 
 
 
   
You are here: Published Weight Loss Studies >

Effect of a dietary herbal supplement containing caffeine and ephedra on weight, metabolic rate, and body composition.

Author: Greenway FL, De Jonge L, Blanchard D, Frisard M, Smith SR

Author affiliation: Pennington Biomedical Research Center, Baton Rouge, LA 70808-4124, USA. greenwfl@pbrc.edu

Publication date & source: 2004.07, Obes Res., 12(7):1152-7.

Publication type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Clinical Trial, Phase III; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

OBJECTIVE: To evaluate the effect of a dietary supplement containing herbal caffeine (70 mg/dose) and ephedra (24 mg/dose; C&E) on metabolic rate, weight loss, body composition, and safety parameters. RESEARCH METHODS AND PROCEDURES: In phase I, 12 healthy subjects with a BMI of 25 to 35 kg/m2 had resting metabolic rate (RMR) measured for 2 hours after ingesting C&E or a placebo on two occasions 1 week apart, followed by a 1-week washout before phase II. In phase II, these 12 and 28 additional subjects were randomized to a 12-week, double-blind trial comparing C&E (3 times/day) to placebo. In phase III, the C&E group was given open-label C&E for 3 months, and the placebo group was given C&E for 6 months. RESULTS: In phase I, C&E gave an average 8 +/- 0.1% (SE) rise in RMR over 2 hours compared with placebo (p < 0.01). In phase II, weight loss at 12 weeks was 3.5 +/- 0.6 kg with C&E compared with 0.8 +/- 0.5 kg with placebo (p < 0.02). The percentage fat lost, shown by DXA, was 7.9 +/- 2.9% with C&E and 1.9 +/- 1.1% with placebo (p < 0.05). Pulse decreased more in the placebo group that in the C&E group (p < 0.03). There were no differences in lipid levels or blood pressure. In phase III, there was a 6-month loss of 7.3% and 7.8% of initial body weight for the groups on placebo and C&E during phase II, respectively. There were no serious adverse events. DISCUSSION: C&E increased RMR significantly by 8% compared with placebo, promoted more weight and fat loss than placebo, and was well tolerated. Copyright 2004 NAASO



Indexes of Weight Loss Research Abstracts
Weight Loss Drugs
Weight Loss Diets
Supplements
Bariatric Surgery
Lifestyle

     
-- advertisements --


Copyright © 2006 by Weight-Loss-Science.com
All inormation is for education purposes only and should not be considered as a medical advice.